Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

COVID-19: Safety and Immunogenicity of a Reduced Dose of the BioNTech/Pfizer BNT162b2 Vaccine in a Healthy Population

Next Previous
X
Search
Trial Profile

COVID-19: Safety and Immunogenicity of a Reduced Dose of the BioNTech/Pfizer BNT162b2 Vaccine in a Healthy Population

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Jul 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elasomeran (Primary) ; Tozinameran (Primary)
  • Indications COVID 2019 infections
  • Focus Pharmacodynamics
  • Acronyms REDU-VAC

    • Most Recent Events

    • 27 Mar 2023 Status changed from recruiting to completed.
    • 01 May 2021 Planned number of patients changed from 200 to 150.
    • 01 May 2021 Number of treatment arms is reduced from 3 to 2, by removing COVID-19 Vaccine Moderna TX mRNA-1273 100 mcg arm and replacing Moderna 50 mcg arm with Pfizer-BioNTech 30 mcg; study design changed from open, non-randomized to double-blind, randomized. Planned patient enrollment decreased from 200 to 150.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top